Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent, Ghent, Belgium; Department of Urology, Ghent University Hospital, Ghent, Belgium.
Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent, Ghent, Belgium.
Int J Biochem Cell Biol. 2018 Jun;99:236-256. doi: 10.1016/j.biocel.2018.04.009. Epub 2018 Apr 11.
Urine contains cellular elements, biochemicals, and proteins derived from glomerular filtration of plasma, renal tubule excretion, and urogenital tract secretions that reflect an individual's metabolic and pathophysiologic state. Despite intensive research into the discovery of urinary biomarkers to facilitate early diagnosis, accurate prognosis and prediction of therapy response in urological cancers, none of these markers has reached widespread use. Their implementation into daily clinical practice is hampered by a substantial degree of heterogeneity in performance characteristics and uncertainty about reliability, clinical utility and cost-effectiveness, in addition to several technical limitations. Extracellular vesicles (EV) have raised interest as a potential source of biomarker discovery because of their role in intercellular communication and the resemblance of their molecular content to that of the releasing cells. We review currently used urinary biomarkers in the clinic and attempts that have been made to identify EV-derived biomarkers for urological cancers. In addition, we discuss technical and methodological considerations towards their clinical implementation.
尿液中包含有细胞成分、生化物质和蛋白质,这些成分源自于血浆的肾小球过滤、肾小管所排泄的物质以及泌尿生殖道的分泌物,反映了个体的代谢和病理生理状态。尽管人们已经进行了大量的研究,以发现有助于早期诊断、准确预测预后和治疗反应的尿液生物标志物,但这些标志物都没有得到广泛应用。由于在性能特征方面存在很大的异质性,并且对于可靠性、临床实用性和成本效益也存在不确定性,此外还有一些技术限制,因此这些标志物在日常临床实践中的应用受到了阻碍。细胞外囊泡 (EV) 因其在细胞间通讯中的作用以及与其释放细胞分子内容的相似性,而成为生物标志物发现的潜在来源,引起了人们的兴趣。我们回顾了目前临床上使用的尿液生物标志物,并探讨了为泌尿外科癌症寻找 EV 衍生生物标志物的尝试。此外,我们还讨论了它们在临床应用方面的技术和方法学考虑。